• Annovis Bio’s lead compound, buntanetap, shows significant enhanced cognitive benefits when combined with GLP-1 agonist dulaglutide in a mouse model
• Buntanetap targets neurodegenerative conditions like Alzheimer’s and Parkinson’s diseases
• GLP-1 agonists, typically used for diabetes, weight loss, and heart conditions, have shown potential in addressing neuroinflammation and neurodegeneration
• The combination treatment results were compelling: While buntanetap alone restored cognitive function to 100% and dulaglutide alone to 80%, the combination restored and also enhanced cognitive function beyond levels seen in healthy controls

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company, announced new preclinical data demonstrating lead compound buntanetap’s potential to synergistically enhance cognition when used in combination with the glucagon-like peptide 1 (GLP-1) agonist dulaglutide (Trulicity(R)) in a mouse model of Alzheimer’s disease (https://ibn.fm/9WpKW).

GLP-1 agonists, such as dulaglutide, are known for their ability to manage blood sugar levels in diabetes patients and are also commonly used for weight loss or heart conditions. However, recent research suggests they also have neuroprotective properties, potentially reducing neuroinflammation and supporting neuronal health. When used alongside buntanetap, dulaglutide appears to amplify the cognitive benefits, suggesting a powerful new approach for treating neurodegenerative conditions.

Buntanetap (formerly Posiphen) works by targeting multiple pathways involved in neurodegenerative diseases. It inhibits the production of neurotoxic proteins that lead to the death of neurons, thereby slowing or stopping disease progression. Dulaglutide, on the other hand, activates the GLP-1 receptor, which has been shown to enhance insulin signaling in the brain, reduce inflammation, and promote cell survival. The combination therapy leverages these complementary mechanisms, aiming to provide a more effective treatment option.

The latest preclinical data builds on 2018 research demonstrating how buntanetap fully restored memory, learning, and synaptic potentiation in an Alzheimer’s mouse model. The company now aimed to determine whether buntanetap combined with dulaglutide would produce a synergistic effect in the same animal model. The results were compelling: while buntanetap alone restored cognitive function to 100% and dulaglutide alone to 80%, the combination restored and also enhanced cognitive function beyond levels seen in healthy controls.

“We are excited to see that buntanetap significantly amplifies the effects of dulaglutide on memory and learning, with a 6- to 10-fold increase in efficacy,” said Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio. “This synergy is particularly important for enhancing treatment outcomes while minimizing potential side effects. As the field of Alzheimer’s research shifts towards combination therapies, we believe our approach holds great promise for offering more effective treatment options for patients.”

The potential for buntanetap combined with dulaglutide to enhance cognitive function represents a significant advancement in the field of neurodegenerative disease treatment. With current treatments offering limited efficacy, this combination therapy could address a critical unmet need in an expanding market.

The neurodegenerative disease treatment market is substantial and growing, driven by an aging population and increasing incidence of conditions like Alzheimer’s Disease. Nearly 7 million Americans are currently suffering from Alzheimer’s Disease, a figure projected to rise to almost 13 million by 2050. Alzheimer’s care costs are expected to reach $360 billion in 2024 and escalate to nearly $1 trillion annually by 2050 (https://ibn.fm/kCfQN). Annovis Bio’s innovative approach with buntanetap, especially when combined with dulaglutide, positions the company to capture a significant market share.

For more information, visit the company’s website at www.AnnovisBio.com, and social channels
LinkedIn, X and YouTube.

NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN